Publication

AI-enhanced rapid lifetime determination method for fast macroscopic and mesoscopic fluorescence lifetime imaging

Claudio Bruschini
2025

Abstract

Fluorescence lifetime imaging (FLI) offers several advantages, including the quantitative imaging of unique biosignatures in biological tissues, studies of drug-target interactions, and tumor margin identification. However, its adoption in surgical environments has been hindered by the time-consuming data acquisition and processing pipeline. In this work, we present an AI-enhanced rapid lifetime determination (RLD) method utilizing the SwissSPAD3 (SS3) detector, capable of acquiring a single frame to generate a large area FLI map. This method has been validated using fluorescence inclusions in tissue-mimicking phantoms, paving the way for complex in-vivo imaging. In conclusion, the AI-enhanced single-shot fluorescence lifetime estimation using the SwissSPAD3 detector represents a significant advancement in the RLD method, with promising potential for fluorescence-guided surgical applications.

Official source

https://infoscience.epfl.ch/entities/publication/fed71ffa-c3a4-4586-b44e-c53ef136cce5

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Graph Chat

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

Claudio Bruschini
2025

Abstract

Official source

https://infoscience.epfl.ch/entities/publication/fed71ffa-c3a4-4586-b44e-c53ef136cce5

About this result

Related concepts (28)

Drug design

Drug design, often referred to as rational drug design or simply rational design, is the inventive process of finding new medications based on the knowledge of a biological target. The drug is most commonly an organic small molecule that activates or inhibits the function of a biomolecule such as a protein, which in turn results in a therapeutic benefit to the patient. In the most basic sense, drug design involves the design of molecules that are complementary in shape and charge to the biomolecular target with which they interact and therefore will bind to it.

Drug discovery

In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered. Historically, drugs were discovered by identifying the active ingredient from traditional remedies or by serendipitous discovery, as with penicillin. More recently, chemical libraries of synthetic small molecules, natural products or extracts were screened in intact cells or whole organisms to identify substances that had a desirable therapeutic effect in a process known as classical pharmacology.

Biological target

A biological target is anything within a living organism to which some other entity (like an endogenous ligand or a drug) is directed and/or binds, resulting in a change in its behavior or function. Examples of common classes of biological targets are proteins and nucleic acids. The definition is contcan refer to the biological target of a pharmacologically active drug compound, the receptor target of a hormone (like insulin), or some other target of an external stimulus.